Moderna Therapeutics

Activities: Research & Development Cardiovascular Digestion Pharmaceutical

Trending Articles

  1. Ariceum Therapeutics' radiopharmaceutical SCLC therapeutic receives FDA Orphan Drug Designation The therapeutic candidate will enter into Phase I/II clinical trials in Q1 of 2025, and has shown significant promise in treating aggressive cancers such as SCLC in preclinical...
  2. Mastering modified-release performance: excipient considerations Imagine a world where enhanced therapeutic efficacy, improved patient compliance and reduced adverse effects are tangible outcomes — even for drugs with short pharmacokinetic...
  3. BioMed X and Merck successfully complete ecDNA oncology research programme The project looked at which genes impact the prevalence of extrachromosomal DNA in cancer cells, and how ecDNA influences the adaptability of these cells
  4. Get ahead in the pharmaceutical industry with a Manufacturing Chemist subscription With a Manufacturing Chemist subscription you receive exclusive access to the latest news, technical insights, regulatory updates, and market intelligence
  5. Weight loss drugs boost big pharma earnings, says AvaTrade This week pharmaceutical giants Eli Lilly and Novo Nordisk both released their financial results for the fourth quarter of 2024, showcasing major developments in their obesity...

Upcoming event

Pharma Packaging and Labelling Forum

5–6 March 2025 | Conference | San Diego, US See all

Related Content

Drug Delivery

Moderna bags $590m US investment to accelerate mRNA-based bird flu vaccine development

The pharmaceutical company's investigational influenza vaccine targets the H5 and H7 varieties, and is currently being prepared for Phase III trials
Manufacturing

Moderna's mRNA manufacturing facility bags Canadian Drug Establishment License

The Canadian facility can now domestically manufacture a range of mRNA vaccines to treat respiratory viruses
Regulatory

Moderna's updated COVID-19 vaccine gets the green light from the FDA

This year's version of the KP.2-targeting vaccine will endeavour to curb local COVID-19 outbreaks
Manufacturing

Moderna announces positive phase 1/2 data for vaccine against Covid-19

Moderna has shared positive phase 1/2 data for its breakthrough combination vaccine against Influenza and Covid-19
Research & Development

How serious is the Pirola strain?

Following the recent news of gradually increasing cases of the new COVID-19 variant Pirola, we sat down with Moderna's VP of Medical Affairs Cesar Sanz Rodriguez to discuss just what people can expect in the coming months
Distribution

Moderna receives positive opinion from the EMA for Spikevax

Moderna has revealed the European Medicine's Agency (EMA) has provided positive opinion on its COVID-19 vaccine Spikevax's marketing authorisation
Research & Development

Moderna discusses mRNA technology advances

Announcements on its mRNA tech, vaccine characterisation and biodistribution were made during the company’s Science and Technology Day event
Subscribe now